Concord Biotech jumps 8% on USFDA nod for Mycophenolate Mofetil oral suspension

Synopsis

Concord Biotech shares saw a significant jump on Wednesday. This surge followed the company's announcement of receiving approval from the USFDA for its Mycophenolate Mofetil for Oral Suspension. This antimetabolite immunosuppressant is used in organ transplant patients.

Shares of Concord Biotech surged as much as 8.46% on Wednesday, hitting an intraday high of Rs 1,264.90, after the company announced that it had received approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL.

According to the company's regulatory filing, the approved product is an antimetabolite immunosuppressant used for the prophylaxis of organ rejection in adult and pediatric patients aged three months and older undergoing kidney, heart, or liver transplants. The medication is administered in combination with other immunosuppressive therapies.

The company highlighted that the approval aligns with its long-term growth strategy and is expected to strengthen its presence in the U.S. pharmaceutical market. Industry estimates suggest that the U.S. market for Mycophenolate Mofetil is valued at approximately US$30 million, providing Concord Biotech with a significant commercial opportunity.

In its disclosure, Concord Biotech stated that the approval was granted by the U.S. Food and Drug Administration (USFDA) and pertains specifically to Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL. The company noted that the approval will enhance its product portfolio and support expansion across both U.S. and international markets. There were no instances of withdrawal, cancellation, or suspension of the approval, and therefore no associated penalties or adverse financial impact.

Stock Performance and Valuation

On the valuation front, the stock is trading at a price-to-earnings (P/E) ratio of 42.56 and a price-to-book (P/B) ratio of 6.13.

Technical Indicators

From a trend perspective, Concord Biotech is trading above six of its eight key simple moving averages (SMAs), reflecting a broadly positive technical setup.

Shareholding Pattern

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)

...moreless

...moreless